Trial results for a virtual reality (VR) treatment for emerging adults with Attention Deficit Hyperactivity Disorder (ADHD) were posted on ClinicalTrials.gov on 2026-01-02, indicating that the 'Virtual Reality + Feedback' group achieved a mean of up to 95% time focused on an objective assessment.
Background
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder often diagnosed in childhood but persisting into adulthood, affecting an individual's ability to focus, control impulses, and manage hyperactivity. Emerging adults (age 18-25) with ADHD frequently face significant challenges with academic tasks such as homework and studying, which require sustained attention and concentration. Traditional treatments include medication and behavioral therapies. Exploring innovative, non-pharmacological interventions like virtual reality could offer new avenues to support this population in managing their symptoms and improving functional outcomes in academic and daily life settings.
Trial design
This completed Phase 3 pilot randomized clinical trial enrolled 60 participants diagnosed with Attention Deficit Hyperactivity Disorder. The study aimed to test a virtual reality program designed to improve focus during homework and studying for emerging adults aged 18-25. Participants were randomized into three groups: a 'Virtual Reality' group using a VR headset, a 'Virtual Reality + Feedback' group using a VR headset with real-time feedback on focus levels, and a 'VR Passthrough' group, which served as a control. The specific primary outcome measures were not detailed in the posted data.
Key results
The trial results provided measurements for two key outcomes across the three intervention groups:
- Objective On-Task Assessment Algorithm (Measurement 1):
- 'VR Passthrough' group: Mean of .86 (Standard Deviation .21) percentage of time focused.
- 'Virtual Reality' group: Mean of .62 (Standard Deviation .35) percentage of time focused.
- 'Virtual Reality + Feedback' group: Mean of .83 (Standard Deviation .27) percentage of time focused.
- Objective On-Task Assessment Algorithm (Measurement 2):
- 'VR Passthrough' group: Mean of .83 (Standard Deviation .04) percentage of time focused.
- 'Virtual Reality' group: Mean of .85 (Standard Deviation .06) percentage of time focused.
- 'Virtual Reality + Feedback' group: Mean of .95 (Standard Deviation .01) percentage of time focused.
- Homework Concentration Index (Measurement 1):
- 'VR Passthrough' group: Mean of 15.93 (Standard Deviation 4.69) units on a scale.
- 'Virtual Reality' group: Mean of 16.17 (Standard Deviation 6.03) units on a scale.
- 'Virtual Reality + Feedback' group: Mean of 17.93 (Standard Deviation 5.57) units on a scale.
- Homework Concentration Index (Measurement 2):
- 'VR Passthrough' group: Mean of 11.82 (Standard Deviation 5.19) units on a scale.
- 'Virtual Reality' group: Mean of 12.75 (Standard Deviation 3.88) units on a scale.
- 'Virtual Reality + Feedback' group: Mean of 12.96 (Standard Deviation 4.37) units on a scale.
What this means
The posted results suggest that a virtual reality program, particularly when combined with feedback, may have a positive impact on the ability of emerging adults with ADHD to maintain focus during academic tasks. The 'Virtual Reality + Feedback' group consistently showed higher mean scores across both measurements of the Objective On-Task Assessment Algorithm, reaching up to a mean of 95% time focused, and also had the highest mean scores for both Homework Concentration Index measurements. These findings indicate that incorporating real-time feedback within a VR environment could be a beneficial strategy for improving concentration in this population. Such an intervention could offer a non-pharmacological tool to help emerging adults with ADHD manage their attention difficulties in educational settings.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06454604, titled 'Virtual Reality Treatment for Emerging Adults With ADHD', were posted on 2026-01-02 on clinicaltrials.gov.
